Pishali Bejestani E, Cartellieri M, Bergmann R, Ehninger A, Loff S, Kramer M, et al.
Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. Oncoimmunlogy. 2017, e1342909. doi: 10.1080/2162402X.2017.1342909.

Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, et al. A novel nanobody-based target module for retargeting  of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunlogy. 2017, 6(4): e1287246. doi: 10.1080/2162402X.2017.1287246.

Feldmann A, Arndt C, Bergmann R, Loff S, Cartellieri M, Bachmann D, et al. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”.  Oncotarget. 2017, 8(19):31368-31385. doi: 10.18632/oncotarget.15572

Bachmann D, AlipertaR, BergmannR, FeldmannA, Koristka S, Arndt C, Loff S, et. al. Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells. Oncotarget 2017.

Mitwasi N, Feldmann A, Bergmann R, Berndt N, Arndt C, Kosistka S, et a. Development of novel target modules for retargeting of UniCAR T cells to GD2-positive tumor cells. Oncotarget 2017; doi: 10.18632/oncotarget.21017.  

Dietrich J, Loff S, Meyer JE, von Bonin M, Hetzenecker M, Spehr J, et al. Targeting leukemia
using an inducible universal chimeric antigen receptor (UniCAR) T cell technology. Cytotherapy 2017, 19(5), S9, Abstract.

Bispecific Antibodies

Aliperta R, Welzel P, Bergmann R, Freudenberg U, Berndt N, Feldmann A, et al. Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy. Scientific Reports. 2017, doi: 10.1038/srep42855



Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and of: a novel modular platform for retargeting of T cells to AML blasts. Blood cancer J. 2016, 6(8):e458, doi: 10.1038/bcj.2016.61.

Loff S, von Bonin M, Dietrich J, Meyer JE, Feldmann A, Arndt C, et al. The UniCAR system:
Inducible CAR T cells for precise reactivity and high efficacy against hematopoietic malignancies.
Cancer Immunology Research. 2016, 4(11), DOI: 10.1158/2326-6066.IMM2016-B099, Abstract.

Modular System

Ehninger A, Cartellieri M, Feldmann A, Arndt C, Koristka S, Loff S, et al. Improved killing of
tumor cells by a novel flexible antibody-based modular T cell retargeting system. Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA, Abstract 2313 DOI: 10.1158/1538-7445.AM2016-2313


Bispecific Antibodies

Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer Journal. 2015 5, e348; doi:10.1038/bcj.2015.73


Cartellieri M, Loff S, von Bonin M, Bejestani EP, Ehninger E, Feldmann A, et al. UniCAR: A novel modular retargeting platform technology for CAR T cells. Blood 2015, 126: 5549, Abstract.

Cartellieri M, Koristka S, Arndt C, et al. A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One. 2014;9(4):e93745.



Koristka S; Cartellieri M; Feldmann A; Arndt C; Loff S; Michalk I, et al. Flexible antigen-speci

Modular antibody complex technology

Arndt C, Feldmann A, von Bonin M, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia. 2014;28(1):59-69.

fic redirection of human regulatory T cells via a novel universal chimeric antigen receptor system. Blood. 2014; 124:3494, Abstract.


Bispecific Antibodies

Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, et al. Retargeting of
regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun. 2013, 42:105-116.

Arndt C, von Bonin M, Cartellieri M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia. 2013;27(4):964-967.

Conventional CAR

Kloss CC, Condomines M, Cartellieri M, Bachmann M and Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 2013, 31:71-75.

2012 - 2007


Cartellieri M, Bachmann M, Feldmann A, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010;2010:956304.

Morgenroth A, Cartellieri M, Schmitz M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate.

Bispecific Antibodies

Stamova S, Feldmann A, Cartellieri M, et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem. 2012;423(2):261-268.

Koristka S, Cartellieri M, Theil A, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol. 2012;188(3):1551-1558.

Feldmann A, Arndt C, Topfer K, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol. 2012;189(6):3249-3259.

Stamova S, Cartellieri M, Feldmann A, et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia. 2011;25(6):1053-1056.

Stamova S, Cartellieri M, Feldmann A, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol. 2011;49(3):474-482

Feldmann A, Stamova S, Bippes CC, et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate. 2011;71(9):998-1011.

Vaccination via SlanDC targeting

Bippes CC, Feldmann A, Stamova S, et al. A novel modular antigen delivery system for immuno targeting of human 6-sulfo LacNAc-positive blood dendritic cells (SlanDCs). PLoS One. 2011;6(1):e16315.